【摘 要】
：
ZJM-289, a novel nitric oxide-donating derivative of 3-n-butylphthalide, has been reported to alleviate cerebral ischemic-reperfusion injury in rats.In this study, we investigated the pharmacokinetic
【机 构】
：
Center of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing, Jiangsu 21
【出 处】
：
第十届全国药物和化学异物代谢学术会议暨第三届国际ISSX/CSSX联合学术会议
论文部分内容阅读
ZJM-289, a novel nitric oxide-donating derivative of 3-n-butylphthalide, has been reported to alleviate cerebral ischemic-reperfusion injury in rats.In this study, we investigated the pharmacokinetic of ZJM-289 and 3-n-butylphthalide in rots following intravenous and intmgastric administration of ZJM-289.Following the intravenous dose, ZJM-289 was eliminated rapidly with a t1/2=19±4 min, CL and V calculated by non-compartmental analysis was 0.22+0.02 L/min/kg and 11.7+ 1.6 L/kg, respectively.AUC0-∝ increased in a dose-proportional manner from 80 to 320 mg/kg intragastric dose of ZJM-289.About 23% of ZJM-289 was converted to 3-n-butylphthalide.ZJM-289 degraded quickly in mouse and rat plasma (t1/2 =20.5-±-0.9, 24.3±0.9 min, respectively).Half-lives of ZJM-289 in microsomes were between 26 and 145 min(mouse < rat < beagle dog < monkey < human).Hydrolysis metabolites M1, M2, M3, M4 and M5, hydroxylation metabolite M6/M7, and glucuronide conjugate M8 were identified by LC-MS/MS in the liver and intestine microsomes.Kinetics of M4 formation in rat and mouse plasma fitted Michaelis-Menten equation and mediated by no more than one enzyme, while in liver microsomes as well as in rat intestine microsomes, M4 formation was mediated by more than one enzyme.The results from this study validated the pro-drug design hypothesis and pharmacological research.
其他文献
目的 建立超高效液相色谱-串联质谱测定血浆中新型酪氨酸酶抑制剂UP302的方法,并用于研究UP302在大鼠、狗、猴和人血浆中的稳定性.方法 血浆中加入内标大豆苷元经2倍体积甲醇沉淀后进行分析.以色谱柱Hypersil Gold C18柱(50 mm×2.1 mm,1.9 μm)为固定相,甲醇为流动相A,5 mmol·L-1甲酸铵水溶液为流动相梯B,进行梯度洗脱.梯度流速恒定为0.2 mL·min-
Aim To investigate the metabolic drug-drug interaction (DDI) potential of rhein through CYP450.Methods Specific substrates of CYP1A, CYP2C, CYP2D, CYP3A and CYP2E were incubated with Rhein (RE) in hum
目的 考察大黄酸通过CYP450代谢酶发生药物代谢相互作用的可能性.方法 在体外人肝和大鼠肝微粒体温孵系统中,大黄酸与CYP1A,CYP2C,CYP2D,CYP3A以及CYP2E的特异性底物共温孵后,考察其抑制强度和类型,采用公式AUCi/AUC=1+ [I]/Ki评价大黄酸在体内可能存在抑制性代谢相互作用的可能性,同时进行大鼠体内药物相互作用的验证.结果 大黄酸是CYP2E1的强抑制剂(IC50
Aim of the study The hepatotoxicity of Radix Polygoni Multiflori (RPM) has received increasing attention over the past few decades, although the hepatotoxicity mechanism of RPM remained uncertain.The
维拉帕米通常以外消旋体的形式用于临床.维拉帕米及其主要代谢产物去甲维拉帕米已证明既是CYP3A酶的机制性抑制剂同时也是CYP3A酶的底物.二者在临床上均表现出非线性药动学特征.体外人肝微粒体实验证明维拉帕米和去甲维拉帕米的代谢以及对CYP3A酶的机制性抑制均具有手性选择性.S-型体外代谢清除率高于R-型，对CYP3A酶的机制性抑制作用更强.基于此，我们建立了简单的机制性自身抑制生理药动学模型预测单
龙胆科花锚为藏药,常用于治疗肝胆疾病,其主要成分1-羟基-2,3,5-三甲氧基咕吨酮(HM-1)的一相代谢是由CYP450酶介导的.为了研究HM-1潜在的药物闻相互作用,本文采用探针底物法结合分子对接技术研究HM-1对人CYP450酶主要亚型(包括CYP1A2,CYP2C9,CYP2D6,CYP2E1和CYP3A4)的抑制作用.结果表明,HM-1对CYP1A2 (IC50=1.06 μM)和CYP
目的 研究聚乙二醇化新型集成干扰素(PEG-IFN-SA)注射液在大鼠体内的药代动力学特征,并与非PEG化的集成干扰素(IFN-SA)进行比较.方法 大鼠分别单次皮下注射(sc)不同剂量PEG-IFN-SA(7、14和28μg/kg)和IFN-SA(7 μg/kg),采用酶联免疫分析(ELI SA)法测定不同时间血清药物浓度,实验数据以DAS 3.0药动程序拟合并计算药动参数.结果 大鼠分别单次s
本文对近年来中药药代动力学的某些研究进展进行综述，包括：中药效应成分整合药代动力学、中药指纹药代动力学、中药新剂型药代动力学以及中药多糖药代动力学研究等，并提出展望。
Objective The aim of the present paper is to study the expression and function of proton-coupled oligopeptide transporters (POTs) in spleen and macrophage, underlying their contribution to innate immu
Primary dysmenorrhea (PDM), a commonly clinical endocrine disorder affecting young women, is associated with endocrinopathy and metabolic abnormalities.Although some physiological and pathological fun